Access OS for transplant and oncology clinics to identify, authorize, and deliver season-long flu antibodies to high-risk patients.

1. Capital is now committed to making full-season influenza antibodies real, so providers need operational infrastructure before launch rather than after first prescriptions arrive.
2. The first commercial beachhead is concentrated immunocompromised patients, which makes a narrow specialty-clinic workflow startup viable from day one.
3. A strain-resilient annual injection creates a different care pathway from seasonal vaccines and exposes the limits of generic reminder and standing-order systems.
4. Beyfortus and Enflonsia comparables imply respiratory prevention biologics are becoming a repeat category, so an enabling access layer can support multiple products over time.

Catalyst. RQ Bio's financing and product profile turn long-acting flu antibodies into an imminent launch category for immunocompromised patients, forcing specialty clinics to operationalize prevention beyond the annual vaccine playbook.

The company sells software to specialty clinics and launch teams that operationalizes annual respiratory prophylaxis for high-risk patients. It builds eligibility cohorts from transplant, oncology, and immunosuppression registries; generates protocol-specific authorization packets; and coordinates outreach, scheduling, inventory reservation, and missed-dose recovery before the season starts. For biotech launch teams, it provides a live view of which sites can find patients, clear coverage, and complete administrations on time. Over time, the startup becomes the system of record for prophylaxis readiness: who qualified, who was delayed by payer or staffing friction, which sites converted outreach into administration, and how seasonal programs perform across patient subgroups.

What's different. Existing manufacturer hub vendors and prior-authorization tools are built for broad specialty-drug fulfillment after a clinician has already decided to treat. This company starts earlier, at cohort construction and seasonal readiness, for a very specific immunocompromised population where eligibility timing matters as much as reimbursement. Its moat comes from prophylaxis-specific workflow data: which transplant and oncology subcohorts qualify, which payer paths clear fastest, which sites lose patients before administration, and how those patterns shift across respiratory biologics and seasons.

Jobs to be done

flowchart LR
  Buyer[Transplant and oncology clinic ops] --> Pain[Eligible high-risk patients are hidden and authorizations are manual]
  Pain --> Product[Flu prophylaxis access OS]
  Product --> Outcome[More on-time administrations before flu season]

Executive takeaways

• The real wedge is not inventing another biologic; it is operationalizing a once-per-season immunocompromised prophylaxis program before the season arrives.
• Customer pain is concrete and budgetable because the workflow sits where prior authorization, specialty pharmacy, outreach, and site-of-care scheduling already break down.
• Adjacent incumbents are strong in their own lanes, but no single player clearly owns the full loop from cohort construction to completed administration for seasonal prophylaxis.
• The beachhead is commercially real but narrow, so long-term upside likely depends on extending the same operating layer into RSV, COVID, and future respiratory prophylaxis launches.

Market definition

U.S. workflow software and services for seasonal respiratory prophylaxis in immunocompromised outpatients, starting with transplant and hematologic oncology programs. The job is to turn a clinically defined high-risk cohort into completed administrations before seasonal risk peaks.

Customer and buyer

Primary users are specialty-pharmacy, ambulatory infusion, and transplant or oncology operations teams that must translate high-risk patient lists into completed prophylaxis. The economic buyer is most likely the chief pharmacy officer, specialty pharmacy leader, or VP of ambulatory operations at an academic health system; manufacturers are a secondary buyer for launch-readiness modules.

Buying triggers

• A new prophylactic monoclonal antibody or adjacent respiratory mAb enters launch planning, and the center realizes a vaccine-reminder workflow is not enough. [1][2][25][26][39]
• High-risk guidance and weak immune-response evidence make missed eligible patients clinically hard to defend, especially in transplant and B-cell-depleted populations. [3][5][6][7][20][22][23][24]
• Manual prior authorization, specialty-pharmacy, and referral steps threaten on-time starts for vulnerable patients and consume scarce staff time. [13][14][15][16][17][35]
• Oncology and specialty-pharmacy leaders already buy digital coordination tools when they reduce burden or improve outcomes, so there is a precedent budget line. [29][31][32]

Willingness to pay

Budget justification is strongest when sold against coordinator labor, care delays, and missed patient capture rather than as generic AI automation. The AMA still finds roughly 40 prior authorizations per physician per week and 95% of physicians reporting care delays, while oncology studies show a 17-step PA workflow and 71% PA rates for oral anticancer drugs. [13][16][17]

Category dynamics

Growth signal 5.7% projected annual growth in U.S. retail prescription drug spending (proxy)

Validation signals

• RQ Bio’s financing and product profile suggest investors and operators expect a real access problem around season-long flu prophylaxis.
• Registry-driven identification and in-house oncology vaccination workflows can materially improve coverage, which implies operations are a real bottleneck.
• Pemgarda and national infusion networks already require explicit provider-location and referral workflows for immunocompromised prophylaxis.

Regulatory & technical constraints

• Drug-specific prior-authorization and medical-necessity rules remain plan-by-plan even as interoperability standards improve.
• Immunocompromised prophylactic antibodies may require healthcare-site administration or monitored follow-up, complicating office-only workflows.
• Vaccination and antivirals remain part of standard influenza prevention and treatment, so software must augment rather than replace existing protocols.
• Transplant and HCT programs need longitudinal infection and immune-status data, not just one-time scheduling.

Competition is fragmented across manufacturer hub services, prior-authorization automation, embedded specialty pharmacy, infusion execution networks, and EHR or oncology population-health platforms. That fragmentation is the opportunity: incumbents own steps, not the full seasonal prophylaxis loop.

Why incumbents do not win by default

• Manufacturer hub services. They handle benefit verification and patient support well, but are typically pharma-funded and reactive to prescriptions rather than clinic-owned annual cohort readiness.
• Prior authorization automation. These tools speed payer interactions but usually begin after staff already know which patient and drug to submit.
• Health-system specialty pharmacy and infusion networks. Embedded pharmacists and infusion providers can execute access and administration, but they do not automatically build seasonal eligibility cohorts across transplant and heme-onc registries.
• EHR and oncology engagement platforms. Population-health and oncology engagement suites can stratify or message patients, but they do not natively close benefits verification, site-of-care routing, and prophylaxis completion for specialty biologics.

This company should start as a prophylaxis access operating layer for large U.S. academic transplant and hematologic oncology programs that will be asked to deliver season-long flu antibodies to immunocompromised outpatients before each season. The customer pain is not scientific uncertainty; it is the operational gap between knowing these patients are high risk and actually identifying, authorizing, scheduling, and completing prophylaxis on time. The best first customer is a top-50 academic medical center with solid-organ transplant, stem-cell transplant, and heme-onc volume large enough to make a once-per-season program visible to pharmacy and ambulatory-operations leadership. The product should stay narrow in year one: registry-based cohort building, protocol-specific authorization packets, outreach work queues, site-of-care routing, and completion tracking. This wedge is stronger than a generic prior-authorization or population-health tool because it closes the full seasonal loop for one high-acuity cohort rather than optimizing one step after prescribing. Go-to-market should treat the first customer, buying trigger, pricing, and distribution channel as one system: sell a paid pre-season pilot when a new flu or adjacent respiratory mAb reaches formulary or launch planning, then convert to an annual site subscription tied to completed seasonal readiness. The medium-term upside comes from reusing the same workflow, payer templates, and benchmark data across RSV, COVID, and future respiratory prophylaxis programs, not from expanding broadly across all specialty drugs. The biggest disconfirming risk is launch timing and coverage uncertainty for first-wave flu antibodies; if the category slips or remains too narrow, the company must prove the product on adjacent respiratory prophylaxis workflows fast. Exact payer policy and administration-setting requirements for the first flu products are still missing from the inputs, so the plan assumes design partners will validate those constraints before heavy integration spend.

Problem

• Transplant and hematologic oncology centers can name the high-risk populations they worry about, but they do not have a repeatable annual workflow to turn registry cohorts into completed prophylaxis before community spread rises.
• Manual prior authorization, specialty-pharmacy coordination, outreach, and site-of-care scheduling consume scarce staff time and create missed-patient risk precisely in the immunocompromised cohorts least protected by routine vaccination.

Solution

• Deploy a clinic-owned prophylaxis access OS that imports transplant and heme-onc registries, applies protocol-specific eligibility rules, generates authorization packets, and routes patients into outreach and scheduling queues before the season.
• Give pharmacy, infusion, and manufacturer launch teams one operating view of who is eligible, who is blocked by payer or logistics friction, and which administrations are complete, delayed, or missed.

Why we win

• The company starts earlier than hub vendors and ePA tools by owning cohort construction and seasonal readiness, not just reimbursement work after a clinician already writes an order.
• Each season compounds proprietary data on immunocompromised eligibility rules, payer turnaround paths, denial reasons, and site-level completion rates that fragmented incumbents do not naturally aggregate.

Milestones

flowchart LR
  Wedge[Academic prophylaxis wedge] --> MVP[Seasonal access MVP]
  MVP --> Proof[Completion and authorization proof]
  Proof --> Expansion[Multi-protocol respiratory expansion]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 3 of the first 5 target centers must show that missed prophylaxis is driven materially by eligibility-capture and access friction rather than lack of clinical demand.
• A lightweight overlay using registry imports and manual QA must go live in under 10 weeks without requiring full EHR write-back.
• Paid pilots must improve completed prophylaxis before the seasonal cutoff by at least 20% or cut authorization turnaround by at least 30% versus baseline.
• Buyers must accept a path to $250K+ annual budget once first-season ROI is visible, rather than relying indefinitely on innovation funds or manufacturer subsidy.
• Adjacent RSV or COVID workflows must be reusable enough to create a second expansion line within 18 months, or the flu-only wedge remains too narrow.

Open diligence questions

• Which exact transplant and heme-onc cohorts can design partners identify reliably from current registry exports without a full data-engineering project?
• What payer documentation package will the first respiratory prophylaxis mAbs require under the medical benefit, and how variable will that be across major plans?
• How often do embedded specialty-pharmacy teams already solve enough of the workflow to reduce willingness to buy a standalone access layer?
• What proof threshold moves this purchase from innovation or launch planning budget into recurring pharmacy or ambulatory-operations budget?
• How similar are RSV, COVID, and flu prophylaxis workflows in practice once site-of-care routing and monitoring requirements are included?

Model sanity

• Revenue engine. Base-case revenue comes from moving from 4 active paid accounts at Y1 exit to 18 by Y3 exit, with most value created by converting pilots into $300K production sites and then attaching a small reporting module layer.
• Must go right. The company has to keep pilot-to-production conversion on roughly a same-season cadence while proving at least one adjacent RSV or COVID workflow reuses the flu playbook.
• Model breaks if. If recurring budget approval or conversion timing slips by about one quarter, the downside case turns cash negative before Y3 finishes.
• Next-round proof. A credible next-round story appears once 12 production sites, one adjacent protocol, and one manufacturer reporting agreement are live by Y2 exit with cash still above a six-month buffer.

Scenarios

Sensitivity

flowchart LR
  Leads[Qualified academic centers] --> PaidPilots[Paid pre-season pilots]
  PaidPilots --> ProductionSites[Annual production subscriptions]
  ProductionSites --> Expansion[RSV or COVID protocol expansion]
  ProductionSites --> Revenue[Core subscription revenue]
  Expansion --> Revenue
  Revenue --> GrossProfit[70% gross profit]
  GrossProfit --> Cash[Cash and runway]

Flags: The base case assumes the flu beachhead does expand into adjacent RSV or COVID workflows; if that reuse fails, the 18-account Y3 path is too aggressive for a single-protocol wedge. · The 70% gross-margin target is only believable if payer-template reuse and implementation playbooks prevent services creep at each new site. · Cash stays healthy in the base case only because hiring remains disciplined and the pre-seed round closes before M1; a one-quarter sales slip likely forces a bridge.

• Launch timing dependence. If long-acting flu antibodies are delayed clinically or commercially, the beachhead market may take longer to materialize than expected. Mitigation: Start with design partners that also manage RSV and other respiratory prophylaxis programs so the workflow engine can support adjacent launches before RQB01-scale products are widespread.
• Workflow integration fatigue. Transplant and oncology clinics may resist another seasonal tool unless it reduces workload immediately. Mitigation: Launch with lightweight registry imports, prebuilt authorization templates, and a services-assisted first season that proves time savings before deeper integrations.
• Payer-policy fragmentation. Coverage rules for new prophylactic antibodies may vary widely across payers and patient cohorts, slowing consistent adoption. Mitigation: Make payer rule logic configurable by site and use the first season to build a reusable knowledge base of authorization paths and denial reasons.